VJHemOnc is committed to improving our service to you

ASH 2019 | Selinexor vs. SOC in penta-exposed MM: STORM & MAMMOTH analysis

VJHemOnc is committed to improving our service to you

Luciano Costa

Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, discusses the analysis of selinexor plus dexamethasone (Sd) vs. conventional care for triple class refractory, penta-exposed multiple myeloma in terms of overall survival (OS). This compared data from the STORM trial (NCT02336815) with real world data from the retrospective MAMMOTH study. While not an replacement for a prospective, randomized trial, this analysis suggested improved OS with Sd vs. conventional care in this group. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter